Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 2/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.40 |
| ▸ | F2R | P25116 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | UBE2M | P61081 | 1/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21264288 | 0.90 | KCNK3 (0.39) | KCNK3KCNK9F2RPDE2AUBE2M | |
| SCHEMBL16442486 | 0.90 | KCNK3 (0.39) | KCNK3KCNK9F2RPDE2AUBE2M | |
| SCHEMBL22639546 | 0.89 | KCNK3 (0.38) | KCNK3KCNK9F2RPDE2ASLC6A2 | |
| SCHEMBL22672504 | 0.88 | PPARG (0.39) | KCNK3KCNK9F2RPDE2ASLC6A2 | |
| SCHEMBL19506515 | 0.86 | TSHR (0.48) | KCNK3KCNK9PDE2ASLC6A2SLC6A4 | |
| SCHEMBL19304412 | 0.86 | KCNK3 (0.38) | KCNK3KCNK9F2RPDE2AUBE2M | |
| SCHEMBL19633875 | 0.85 | KCNK3 (0.38) | KCNK3KCNK9F2RPDE2AUBE2M | |
| SCHEMBL20534572 | 0.83 | FFAR4 (0.45) | KCNK3KCNK9HPGDRXRARXRB | |
| SCHEMBL24105893 | 0.81 | F2R (0.39) | KCNK3KCNK9F2RUBE2MDCUN1D1 | |
| SCHEMBL23095064 | 0.80 | CA1 (0.46) | TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-10696713-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190194245-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2019-06-27 | — | — | US | disclosed |
| US-10266560-B2 | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10208081-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170334893-A1 | Isoxazole Analogs as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334893-A1 | Isoxazole Analogs as FXR Agonists and Methods of Use Thereof | FXR1, SLC10A1, NR1H4 | KCNK3 3439/4885KCNK9 4066/4885F2R 613/4885 |
| US-10696713-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | KCNK3 3702/4885KCNK9 3438/4885F2R 392/4885 |
| US-10208081-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | KCNK3 3702/4885KCNK9 3438/4885F2R 392/4885 |
| US-10266560-B2 | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | KCNK3 3268/4885KCNK9 2968/4885F2R 285/4885 |
| US-20190194245-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | KCNK3 3702/4885KCNK9 3438/4885F2R 392/4885 |
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, NR1H4, SLC10A2 | KCNK3 2936/4885KCNK9 3302/4885F2R 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.